Lecture 11 Clinical Pharmacology

20 views3 pages
22 Apr 2012
Lecture 11 PCL201 Clinical Pharmacology
Bioavailability (F)
Fraction of uncharged drug reaching systemic circulation
Measure as AUC
Measures extent of absorption and first pass
F = f(1-E) (f = absorption)
IV; 100%, rapid onset
IM; 75-100%, larger volume than SC
SC; 75-100%, smaller volume than IM
PO; 5-100%, convenient, 1st pass
PR; 30-100%, less 1st pass than PO
Inhalation; 5-100%, rapid onset
Transdermal; 80-100%, slow onset, prolonged duration
Oral dosing
Capsule disintegrates, dissolves and absorbed via GIT
1st pass effect
reduced bioavailability
[Dr]plasma slow to increase (while absorption takes place)
[Dr]plasma decreases slightly as it equilibrates with all compartments
[Dr]plasma decreases with elimination
1. [Dr]plasma rising slope not as steep as IV
2. equivalent IV/PO dose PO has lower Cmax
3. PO longer to reach Cther after reaching Cmax
Cmax: peak [drug]
Tmax: time at Cmax
AUC: []/time: extent of absorption, amount of drug in plasma bioavailability
Measure bioavailability compare AUC to IV
Bioavailability = (AUC X)/(AUC IV)
Used to establish bioequivalence of generic drug: (AUC trade)/(AUC generic) must be 80-
Compare bioequivalence
[drug] that reaches systemic unchanged
measure extent of absorption
compare routes of administration
Half life t ½
time to decrease [drug] to half of previous value
t ½ = 0.693/k
Rule of thumb: 5 half lives for 96.9% drug removal
Unlock document

This preview shows page 1 of the document.
Unlock all 3 pages and 3 million more documents.

Already have an account? Log in

Get OneClass Notes+

Unlimited access to class notes and textbook notes.

YearlyBest Value
75% OFF
$8 USD/m
$30 USD/m
You will be charged $96 USD upfront and auto renewed at the end of each cycle. You may cancel anytime under Payment Settings. For more information, see our Terms and Privacy.
Payments are encrypted using 256-bit SSL. Powered by Stripe.